Ñî¹óåú´«Ã½Ò•îl

Researchers hope to shed light on conditions such as schizophrenia, epilepsy, cerebral palsy, intellectual disability and rare forms of dementia. (Sample, 9/16)

A large international study, published in Nature Medicine today, found that a liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. (9/16)

In a discovery that challenges long-standing assumptions about necrotizing enterocolitis, a sudden and often fatal intestinal illness that affects premature infants, researchers at Washington University School of Medicine in St. Louis have identified previously unknown predictors for the disease. (9/16)

In a study of blood samples from more than 100 participants with MS, Mass General Brigham researchers detected increased EBV lytic activity in immune cells up to three months before MS relapse and discovered that these cells also showed elevated expression of genes linked to MS risk. (9/16)

New UNSW research published in Translational Psychiatry shows a gut supplement can repair opioid-related damage in rat pups, raising hopes for a future treatment for babies exposed to opioids in the womb. (9/16)

Use of adjunctive azithromycin increased among women undergoing unscheduled cesarean deliveries and postpartum infection rates fell after a landmark trial showed the antibiotic's benefits in this setting, according to a difference-in-differences analysis. (Rudd, 9/14)

GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate. (Liu, 9/13)

Definium Therapeutics said Monday that its LSD therapy helped patients with anxiety in a second late-stage trial, setting up the company to seek the first approval of a psychedelic drug for anxiety. (Chen, 9/14)

Vera Therapeutics said Tuesday that its recently approved drug Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic autoimmune kidney disease, according to final, two-year results from a Phase 3 clinical trial. (Feuerstein, 9/15)